Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.48 |
| ▸ | EGLN1 | Q9GZT9 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.46 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.44 |
| ▸ | GLO1 | Q04760 | 1/20 | 0.44 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.43 |
| ▸ | MGAM | O43451 | 1/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
| ▸ | SI | P14410 | 1/20 | 0.43 |
| ▸ | MGAM2 | Q2M2H8 | 1/20 | 0.43 |
| ▸ | SOAT1 | P35610 | 1/20 | 0.43 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 2/20 | 0.40 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16045663 | 0.92 | ALDH1A1 (0.46) | ALDH1A1EGLN1LMNAHSD17B10NPSR1 | |
| SCHEMBL1418707 | 0.85 | ALDH1A1 (0.56) | ALDH1A1EGLN1LMNAHSD17B10NPSR1 | |
| SCHEMBL247694 | 0.85 | ALDH1A1 (0.56) | ALDH1A1EGLN1LMNAHSD17B10NPSR1 | |
| Pyridine SCHEMBL27786003 | 0.83 | MEN1 (0.41) | ALDH1A1EGLN1LMNAHSD17B10GAA | |
| Oxalic Acid SCHEMBL11125356 | 0.82 | ALDH1A1 (0.53) | ALDH1A1EGLN1LMNAHSD17B10NPSR1 | |
| Oxalic Acid SCHEMBL27581907 | 0.82 | ALDH1A1 (0.53) | ALDH1A1EGLN1LMNAHSD17B10NPSR1 | |
| Water SCHEMBL1097795 | 0.82 | ALDH1A1 (0.53) | ALDH1A1EGLN1LMNAHSD17B10NPSR1 | |
| SCHEMBL18979198 | 0.82 | ALDH1A1 (0.53) | ALDH1A1EGLN1LMNAHSD17B10NPSR1 | |
| SCHEMBL98770 | 0.82 | — | — | |
| SCHEMBL29896398 | 0.82 | ALDH1A1 (0.53) | ALDH1A1EGLN1LMNAHSD17B10NPSR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-102321030-A | The heterocycle inhibitor of MEK and method of use thereof | ARRAY BIOPHARMA INC | 2012-01-18 | — | — | CN | claimed |
| EP-2470894-B1 | SYNTHETIC MYCOTOXIN ADSORBENTS AND METHODS OF MAKING AND UTILIZING THE SAME | ALLTECH INC (US) | 2021-12-29 | — | — | EP | disclosed |
| EP-2433937-B1 | Substituted-quinoxaline-type-piperidine compounds and the uses thereof | PURDUE PHARMA LP (US) | 2016-06-29 | — | — | EP | disclosed |
| EP-2086958-B1 | SUBSTITUTED-QUINOXALINE-TYPE-PIPERIDINE COMPOUNDS AND THE USES THEREOF | PURDUE PHARMA LP (US) | 2015-01-14 | — | — | EP | disclosed |
| US-RE45274-E1 | Synthetic mycotoxin adsorbents and methods of making and utilizing the same | ALLTECH, INC. (US) | 2014-12-02 | — | — | US | disclosed |
| EP-2324013-B3 | SUBSTITUTED-QUINOXALINE-TYPE BRIDGED-PIPERIDINE COMPOUNDS AND THE USES THEREOF | PURDUE PHARMA LP (US) | 2014-10-22 | — | — | EP | disclosed |
| US-8426541-B2 | Synthetic mycotoxin adsorbents and methods of making and utilizing the same | ALLTECH, INC. (US) | 2013-04-23 | — | — | US | disclosed |
| WO-2012085648-A9 | PHOSPHORUS-SUBSTITUTED QUINOXALINE-TYPE PIPERIDINE COMPOUNDS AND USES THEREOF | PURDUE PHARMA L.P. (US) | 2013-03-21 | — | — | WO | disclosed |
| EP-2537844-A1 | Substituted-quinoxaline-type bridged-piperidine compounds and the uses thereof | Purdue Pharma L.P. (US) | 2012-12-26 | — | — | EP | disclosed |
| EP-2324013-B1 | SUBSTITUTED-QUINOXALINE-TYPE BRIDGED-PIPERIDINE COMPOUNDS AND THE USES THEREOF | PURDUE PHARMA LP (US) | 2012-09-19 | — | — | EP | disclosed |
| EP-2433935-A1 | Substituted-quinoxaline-type-piperidine compounds and the uses thereof | Purdue Pharma LP (US) | 2012-03-28 | — | — | EP | disclosed |
| CN-102321030-A | The heterocycle inhibitor of MEK and method of use thereof | ARRAY BIOPHARMA INC | 2012-01-18 | — | — | CN | disclosed |
| CN-102304086-A | Heterocyclic inhibitors of MEK and methods of use thereof | ASTRAZENECA AB | 2012-01-04 | — | — | CN | disclosed |
| WO-2011122815-A2 | NOVEL QUINOXALINE DERIVATIVES | DONG-A PHARM.CO.,LTD. (KR) | 2011-10-06 | — | — | WO | disclosed |
| US-20110178090-A1 | SUBSTITUTED-QUINOXALINE-TYPE BRIDGED-PIPERIDINE COMPOUNDS AND THE USES THEREOF | PURDUE PHARMA L.P. | 2011-07-21 | — | — | US | disclosed |
| WO-2011031562-A1 | SYNTHETIC MYCOTOXIN ADSORBENTS AND METHODS OF MAKING AND UTILIZING THE SAME | ALLTECH, INC. (US) | 2011-03-17 | — | — | WO | disclosed |
| US-20110054132-A1 | SYNTHETIC MYCOTOXIN ADSORBENTS AND METHODS OF MAKING AND UTILIZING THE SAME | ALLTECH, INC. (US) | 2011-03-03 | — | — | US | disclosed |
| WO-2010010458-A1 | SUBSTITUTED-QUINOXALINE-TYPE BRIDGED-PIPERIDINE COMPOUNDS AND THE USES THEREOF | PURDUE PHARMA L.P. (US) | 2010-01-28 | — | — | WO | disclosed |
| WO-2009027820-A2 | SUBSTITUTED-QUINOXALINE-TYPE-PIPERIDINE COMPOUNDS AND THE USES THEREOF | PURDUE PHARMA L.P. (DE) | 2009-03-05 | — | — | WO | disclosed |
| US-4495351-A | FOR UROGENVITAL DISORDERS | VEB ARZNEIMITTELWERK DRESDEN (DD) | 1985-01-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110178090-A1 | SUBSTITUTED-QUINOXALINE-TYPE BRIDGED-PIPERIDINE COMPOUNDS AND THE USES THEREOF | OPRK1, OPRD1, P2RX4 | ALDH1A1 196/4885EGLN1 474/4885LMNA 2889/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.